WHO released the data from their mega trial of 4 potential treatments (including Remdesivir) which i have summarized below:
- Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a
- COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control
- 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug
- Death rate ratios were: Remdesivir (301/2743 active vs 303/2708 control), Hydroxychloroquine (104/947 vs 84/906 control), Lopinavir (148/1399 vs 146/1372 control) and Interferon (243/2050 vs 216/2050 control)
- Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay
This study shows that there is currently no treatment that significantly reduces Covid-19 mortality. Note that it does still need to be peer reviewed.
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
- Forums
- ASX - By Stock
- Remdesivir
WHO released the data from their mega trial of 4 potential...
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 97.0¢ | $2.821M | 2.832M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20688 | 97.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 35000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20688 | 0.975 |
6 | 137742 | 0.970 |
6 | 111862 | 0.965 |
5 | 79094 | 0.960 |
1 | 5200 | 0.955 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 35000 | 3 |
0.995 | 69662 | 5 |
1.000 | 33108 | 4 |
1.005 | 20000 | 1 |
1.010 | 73320 | 2 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online